3-(2-(5-Amino-3-aryl-1H-pyrazol-1-yl) thiazol-4-yl)-2H-chromen-2-ones as Potential Anticancer Agents: Synthesis, Anticancer Activity Evaluation and Molecular Docking Studies

In an effort to design and develop efficient anticancer agents here, we report the synthesis, anticancer activity and molecular docking studies of new 3-(2-(5 amino-3-aryl-1H-pyrazol-1-yl)thiazol-4-yl)-2H-chromen-2-ones. The target products were synthesized via a facile one pot multicomponent approach by utilizing various substituted 3-(2-bromoacetyl)coumarins(1a-j), thiosemicarbazide (2) and benzoylacetonitriles (3 a-c) with excellent yields. All the synthesized compounds were characterized by physical and analytical methods (IR, (HNMR)-H-1, (CNMR)-C-13 and Mass spectra) and screened for their anti cancer property against five human cancer cell lines [L1210, CEM, DU-145, HeLa, and MCF-7]. Among the tested compounds, 6-diethylamino substituted compound 4k exhibited excellent potency against tested cancer cell lines, whereas 6,8-Ditert-butyl substituted compound 4j shown promising activity against DU-145 and MCF-7 cancer cell lines with IC50 values of 7 +/- 1 and 9 +/- 6M. Molecular docking study was carried out in order to understand the most plausible binding site interactions of the compounds with human Epidermal growth factor receptor (EGFR).